Drug Approval | January 30, 2023
FDA approves Keytruda as adjuvant treatment for non-small cell lung cancer
Approval marks fifth indication for KEYTRUDA-based regimens in NSCLC and 34th indication for KEYTRUDA in the US
Approval marks fifth indication for KEYTRUDA-based regimens in NSCLC and 34th indication for KEYTRUDA in the US
This clearance allows the company to initiate a clinical trial for patients with an ileal pouch-anal anastomosis
It will help upgrade the infrastructure and technologies of the country's biopharmaceuticals and in-vitro diagnostic industry
The company has reported total income of Rs. 547.33 crores during the period ended December 31, 2022
The company has reported total income of Rs. 78.50 crores during the period ended December 31, 2022
Standalone Q3 FY23 revenue stood at Rs. 626.5 crore as against Rs. 594.8 crore, a growth of 5% YoY
The United States Food and Drug Administration (USFDA) conducted an inspection at Gland Pharma Limited API Facility at JNPC, Visakhapatnam
The Durezol brand and generic had US sales of approximately US $40 million MAT for the most recent twelve months ending in Nov 2022 according to IQVIA
The company will engage with the agency to resolve the import alert at the earliest.
The company has reported total income of Rs. 211.36 crores during the period ended December 31, 2022
Subscribe To Our Newsletter & Stay Updated
